---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-12/23 inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: IL-12/23 inhibitors. Topics: Biologics guideline: ustekinumab recommendation, Ustekinumab: FDA-approved indication and weight-based dosage every 12 weeks, Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12, Decision aid: ustekinumab, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/il-12-23-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-12/23 inhibitors

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 IL-12/23 Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

### Biologics guideline: ustekinumab recommendation

> “Ustekinumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.8-2"></a>

### Ustekinumab: FDA-approved indication and weight-based dosage every 12 weeks

> “STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.”
> “For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.”
> “For patients weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.”

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

<a id="topic-2.2.2.1.8-3"></a>

### Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12

| Outcome at Week 12, n (%) | Ps STUDY 1 placebo (N=255) | Ps STUDY 1 STELARA 45 mg (N=255) | Ps STUDY 1 STELARA 90 mg (N=256) | Ps STUDY 2 placebo (N=410) | Ps STUDY 2 STELARA 45 mg (N=409) | Ps STUDY 2 STELARA 90 mg (N=411) |
| --- | --- | --- | --- | --- | --- | --- |
| PASI 75 response | “8 (3%)” | “171 (67%)” | “170 (66%)” | “15 (4%)” | “273 (67%)” | “311 (76%)” |
| PGA of cleared or minimal | “10 (4%)” | “151 (59%)” | “156 (61%)” | “18 (4%)” | “277 (68%)” | “300 (73%)” |

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

<a id="topic-2.2.2.1.8-4"></a>

### Decision aid: ustekinumab

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Ustekinumab | “34%” | “84–86% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.8-5"></a>

### Network meta-analysis: ustekinumab compared with other biologics and oral agents

> “Anti‐IL17 class had a better chance of reaching PASI 90 using SUCRA (versus placebo: RR 25.58, 95% CI 21.64 to 30.23; SUCRA = 99.2), followed by anti‐IL23 (versus placebo: RR 22.25, 95% CI 18.70 to 26.48; SUCRA = 86.4), anti‐IL12/23 (versus placebo: RR 17.71, 95% CI 14.68 to 21.36; SUCRA = 71.5), and anti‐TNF‐alpha (versus placebo: RR 13.33, 95% CI 11.21 to 15.85; SUCRA = 57.1).”
> “Ustekinumab was superior to certolizumab (RR 1.43, 95% CI 1.07 to 1.92).”
> “Secukinumab, ixekizumab, brodalumab, risankizumab, and bimekizumab were more effective than ustekinumab.”
> “Adalimumab, tildrakizumab, and ustekinumab were superior to etanercept, deucravacitinib, and apremilast.”
> “For reaching PASI 90 at 52 weeks, risankizumab was more effective than ustekinumab (RR 1.73, 95% CI 1.46 to 2.05).”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg | “69.7 (66.3-73.1)” | “43.9 (40.2-47.9)” | “16.7 (14.4-19.3)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
